Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2015

Open Access 01-12-2015 | Research

Mapping the EQ-5D index from the cystic fibrosis questionnaire-revised using multiple modelling approaches

Authors: Sarah Acaster, Binny Pinder, Clara Mukuria, Amanda Copans

Published in: Health and Quality of Life Outcomes | Issue 1/2015

Login to get access

Abstract

Background

This study was designed to develop a mapping algorithm to estimate EQ-5D utility values from Cystic Fibrosis Questionnaire-Revised (CFQ-R) data.

Methods

A cross-sectional survey of adults with cystic fibrosis (CF) was conducted in the UK. The survey consisted of the CFQ-R, the EQ-5D and a background questionnaire. Eight regression models, exploring item and domain level predictors, were evaluated using three different modelling approaches: ordinary least squares (OLS), Tobit, and a two-part model (TPM). Predictive performance in each model was assessed by intraclass correlations, information criteria (Bayesian information criteria and Alkaike information criteria), and root mean square error (RMSE).

Results

The survey was completed by 401 participants. For all modelling approaches the best performing item level model included all items, and the best performing domain level model included the CFQ-R Physical-, Role- and Emotional-functioning, Vitality, Eating Disturbances, Weight, and Digestive Symptoms domains and a selection of squared terms. Overall, the item level TPM, including age and gender covariates performed best within sample validation, but OLS and TPM domain models with squared terms performed best out-of-sample and are recommended for mapping purposes.

Conclusions

Domain and item level models using all three modelling approaches reached an acceptable degree of predictive performance with domain models performing well in out-of-sample validation. These mapping functions can be applied to CFQ-R datasets to estimate EQ-5D utility values for economic evaluations of interventions for patients with cystic fibrosis. Further research evaluating model performance in an independent sample is encouraged.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: Strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med. 2011;183:1463–71.CrossRefPubMed Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: Strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med. 2011;183:1463–71.CrossRefPubMed
2.
go back to reference Royce FH, Carl JC. Health-related quality of life in cystic fibrosis. Curr Opin Pediatr. 2011;23:535–40.CrossRefPubMed Royce FH, Carl JC. Health-related quality of life in cystic fibrosis. Curr Opin Pediatr. 2011;23:535–40.CrossRefPubMed
3.
go back to reference Quittner AL. Measurement of quality of life in cystic fibrosis. Curr Opin Pulm Med. 1998;4:326–31.CrossRefPubMed Quittner AL. Measurement of quality of life in cystic fibrosis. Curr Opin Pulm Med. 1998;4:326–31.CrossRefPubMed
4.
go back to reference Wahl AK, Rustoen T, Hanestad BR, Gjengedal E, Moum T. Living with cystic fibrosis: impact on global quality of life. Heart Lung. 2005;34:324–31.CrossRefPubMed Wahl AK, Rustoen T, Hanestad BR, Gjengedal E, Moum T. Living with cystic fibrosis: impact on global quality of life. Heart Lung. 2005;34:324–31.CrossRefPubMed
5.
go back to reference Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat L. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest. 2002;121:64–72.CrossRefPubMed Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat L. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest. 2002;121:64–72.CrossRefPubMed
6.
go back to reference Quittner AL, Buu A, Messer MS, Modi AC, Watrous M. Development and validation of the cystic fibrosis questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest. 2005;128:2347–54.CrossRefPubMed Quittner AL, Buu A, Messer MS, Modi AC, Watrous M. Development and validation of the cystic fibrosis questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest. 2005;128:2347–54.CrossRefPubMed
7.
go back to reference Quittner AL, Buu A, Watrous M, Davis MA. The cystic fibrosis questionnaire (CFQ): user’s manual. Washington, DC: Cystic Fibrosis Foundation; 2000. Quittner AL, Buu A, Watrous M, Davis MA. The cystic fibrosis questionnaire (CFQ): user’s manual. Washington, DC: Cystic Fibrosis Foundation; 2000.
8.
go back to reference Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354:241–50.CrossRefPubMed Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354:241–50.CrossRefPubMed
9.
go back to reference Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al. National hypertonic saline in cystic fibrosis (NHSCF) study group: a controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354:229–40.CrossRefPubMed Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al. National hypertonic saline in cystic fibrosis (NHSCF) study group: a controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354:229–40.CrossRefPubMed
11.
go back to reference Sauerland S, Weiner S, Dolezalova K, Angrisani L, Noguera CM, Garcia-Caballero M, et al. Mapping utility scores form a disease-specific quality of life measure in bariatric surgery patients. Value Health. 2009;12:364–70.CrossRefPubMed Sauerland S, Weiner S, Dolezalova K, Angrisani L, Noguera CM, Garcia-Caballero M, et al. Mapping utility scores form a disease-specific quality of life measure in bariatric surgery patients. Value Health. 2009;12:364–70.CrossRefPubMed
12.
go back to reference Franks P, Lubetkin EI, Gold MR, Tancredi DJ, Jia H. Mapping the SF-12 to the EuroQol EQ-5D index in a national US sample. Med Decis Making. 2004;24:247–54.CrossRefPubMed Franks P, Lubetkin EI, Gold MR, Tancredi DJ, Jia H. Mapping the SF-12 to the EuroQol EQ-5D index in a national US sample. Med Decis Making. 2004;24:247–54.CrossRefPubMed
13.
go back to reference Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference –based score from published studies (where patient level data are not available). Value Health. 2008;11:1131–43.CrossRefPubMed Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference –based score from published studies (where patient level data are not available). Value Health. 2008;11:1131–43.CrossRefPubMed
14.
go back to reference Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013;16:202–10.CrossRefPubMed Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013;16:202–10.CrossRefPubMed
15.
go back to reference Brazier JR, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11:215–25.CrossRefPubMed Brazier JR, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11:215–25.CrossRefPubMed
16.
go back to reference Rabin R, de Charro F. EQ-D5: a measure of health status from the EuroQol group. Ann Med. 2001;33:337–43.CrossRefPubMed Rabin R, de Charro F. EQ-D5: a measure of health status from the EuroQol group. Ann Med. 2001;33:337–43.CrossRefPubMed
18.
go back to reference Group EQ. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.CrossRef Group EQ. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.CrossRef
20.
21.
go back to reference Dakin H, Petrou S, Haggard M, Benge S, Williamson I. Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire. Qual Life Res. 2010;19:65–80.CrossRefPubMed Dakin H, Petrou S, Haggard M, Benge S, Williamson I. Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire. Qual Life Res. 2010;19:65–80.CrossRefPubMed
22.
go back to reference Chuang L-H, Kind P. Converting the SF-12 into the EQ-5D: an empirical comparison of methodologies. Pharmacoeconomics. 2009;27:491–505.CrossRefPubMed Chuang L-H, Kind P. Converting the SF-12 into the EQ-5D: an empirical comparison of methodologies. Pharmacoeconomics. 2009;27:491–505.CrossRefPubMed
23.
go back to reference Huang IC, Frangakis C, Atkinson MJ, Willke RJ, Leite WL, Vogel WB, et al. Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease. Health Serv Res. 2008;43:327–39.CrossRefPubMedCentralPubMed Huang IC, Frangakis C, Atkinson MJ, Willke RJ, Leite WL, Vogel WB, et al. Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease. Health Serv Res. 2008;43:327–39.CrossRefPubMedCentralPubMed
24.
go back to reference Quittner AL, Sawicki GS, McMullen A, Rasouliyan L, Pasta DJ, Yegin A, et al. Psychometric evaluation of the cystic fibrosis questionnaire-revised in a national, US sample. Qual Life Res. 2012;21:1279–90.CrossRefPubMed Quittner AL, Sawicki GS, McMullen A, Rasouliyan L, Pasta DJ, Yegin A, et al. Psychometric evaluation of the cystic fibrosis questionnaire-revised in a national, US sample. Qual Life Res. 2012;21:1279–90.CrossRefPubMed
25.
go back to reference Bradley JM, Blume SW, Balp M-M, Honeybourne D, Elborn JS. Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study. Eur Respir J. 2013;41:571–7.CrossRefPubMed Bradley JM, Blume SW, Balp M-M, Honeybourne D, Elborn JS. Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study. Eur Respir J. 2013;41:571–7.CrossRefPubMed
26.
27.
go back to reference Rowan DL, Brazier JE, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes. 2009;7:27.CrossRef Rowan DL, Brazier JE, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes. 2009;7:27.CrossRef
28.
go back to reference Sanders DB, Bittner RCL, Rosenfeld M, Redding GJ, Goss CH. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol. 2011;46:393–400.CrossRefPubMed Sanders DB, Bittner RCL, Rosenfeld M, Redding GJ, Goss CH. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol. 2011;46:393–400.CrossRefPubMed
29.
go back to reference Jarad NA, Higgs S, Jeffcote T, Giles K. Factors associated with reduced FEV1 in adult patients with cystic fibrosis in a relatively affluent area. Chron Respir Dis. 2005;2:133–7.CrossRefPubMed Jarad NA, Higgs S, Jeffcote T, Giles K. Factors associated with reduced FEV1 in adult patients with cystic fibrosis in a relatively affluent area. Chron Respir Dis. 2005;2:133–7.CrossRefPubMed
Metadata
Title
Mapping the EQ-5D index from the cystic fibrosis questionnaire-revised using multiple modelling approaches
Authors
Sarah Acaster
Binny Pinder
Clara Mukuria
Amanda Copans
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2015
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-015-0224-6

Other articles of this Issue 1/2015

Health and Quality of Life Outcomes 1/2015 Go to the issue